{"organizations": [], "uuid": "72b7903dd21492bd2177aa9396f6f851a628e243", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180222.html", "section_title": "Archive News &amp; Video for Thursday, 22 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-sobi-q4-core-profit-beats-expectat/brief-sobi-q4-core-profit-beats-expectations-idUSFWN1QC02H", "country": "US", "domain_rank": 408, "title": "BRIEF-‍Sobi Q4 core profit beats expectations ​", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.218, "site_type": "news", "published": "2018-02-22T15:07:00.000+02:00", "replies_count": 0, "uuid": "72b7903dd21492bd2177aa9396f6f851a628e243"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-sobi-q4-core-profit-beats-expectat/brief-sobi-q4-core-profit-beats-expectations-idUSFWN1QC02H", "ord_in_thread": 0, "title": "BRIEF-‍Sobi Q4 core profit beats expectations ​", "locations": [], "entities": {"persons": [{"name": "anna ringstrom", "sentiment": "none"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "ebita", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 22 (Reuters) - Swedish Orphan Biovitrum:\n* SAYS ‍SOBI EXPECTS TOTAL REVENUES FOR FULL-YEAR TO BE IN RANGE OF SEK 7,500 - 7,700 M.​\n* SAYS ‍GROSS MARGIN IS EXPECTED TO BE AT LEAST 70 PER CENT.​\n* SAYS ‍SOBI EXPECTS EBITA FOR FULL-YEAR TO BE IN RANGE OF SEK 2,500 - 2,700 M.​\n* Q4 ‍EARNINGS PER SHARE OF SEK 1.33​ * Q4 ‍EBITA ROSE 195 PER CENT TO SEK 619 M​ * Q4 ‍TOTAL REVENUES WERE SEK 1,875 M (1,292), AN INCREASE OF 45 PER CENT​\n* REUTERS POLL: SOBI Q4 EBITA WAS SEEN AT 565 MILLION SEK, REVENUES AT 1,759 MILLION\n* SAYS TOTAL REVENUES FOR THE QUARTER FOR THE HAEMOPHILIA FRANCHISE WERE SEK 985 M (451), INCLUDING ROYALTY REVENUES OF SEK 314 M (277)​\n* SAYS PRODUCT SALES WERE SEK 671 M (174), WHEREOF SEK 540 M (135) FROM ELOCTA AND SEK 131 M (39) FROM ALPROLIX​\n* REUTERS POLL: SOBI 2018 SALES SEEN AT 7,899 MILLION SEK, EBITA AT 2,833 MILLION\n* Source text for Eikon: Further company coverage: (Reporting By Anna Ringstrom)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-22T15:07:00.000+02:00", "crawled": "2018-02-23T15:32:58.002+02:00", "highlightTitle": ""}